PMID- 28625246
OWN - NLM
STAT- MEDLINE
DCOM- 20181018
LR  - 20181018
IS  - 2095-4352 (Print)
VI  - 29
IP  - 6
DP  - 2017 Jun
TI  - [Effects of high flow hemodialysis on the biomarker of myocardium injury and the 
      cardiac function related records in uremia patients].
PG  - 547-550
LID - 10.3760/cma.j.issn.2095-4352.2017.06.014 [doi]
AB  - OBJECTIVE: To investigate the effects of high flow hemodialysis (HFHD) on cardiac 
      function in uremia patients. METHODS: A prospective randomized controlled study 
      was conducted. Sixty patients who were diagnosed with uremia, taken maintenance 
      hemodialysis (MHD) and 30 healthy controls admitted to the Second People's 
      Hospital of Guiyang from December 2014 to June 2015 were enrolled. They were 
      randomly divided into two groups: HFHD group (HFHD three times a week) and the 
      routine hemodialysis group (HD group, HD three times a week), with 30 in each 
      group. Patients in each group were received hemoperfusion and hemofiltration once 
      a month. Before the treatment and 6 months after the treatment, venous blood from 
      all the patients were collected for testing the brain natriuretic peptide (BNP), 
      cardiac troponin T (cTnT) and the ultrasound cardiograph were done at the same 
      period by a special person, the left ventricular end diastolic diameter (LVEDD), 
      left ventricular end systolic diameter (LVESD), the left ventricular end 
      diastolic volume (LVEDV), left ventricular end systolic volume (LVESV), left 
      ventricular posterior wall thickness (LVPWT), interventricular septum thickness 
      (IVST), early and late diastolic blood flow to the largest ratio (E/A), left 
      ventricular ejection fraction (LVEF), left ventricular mass index (LVMI) were 
      recorded. RESULTS: Compared with the health control group, BNP, cTnT, LVEDD, 
      LVESD, LVESV, LVPWT, IVST were significantly increased, LVEDV were significantly 
      lowered before treatment in the HD group and HFHD group. But no significant 
      differences in the above indexes and E/A, LVEF, LVMI between two groups were 
      found. Compared with the data before treatment, the BNP, LVPWT were significantly 
      lowered after treatment in HD group [BNP (ng/L): 641.50+/-60.09 vs. 2676.20+/-454.30, 
      LVPWT (mm): 10.57+/-1.16 vs. 12.57+/-1.41, both P < 0.05]. The BNP, LVPWT were 
      significantly lowered in HFHD group as compared with HD group [BNP (ng/L): 
      253.10+/-48.77 vs. 641.50+/-60.09, LVPWT (mm): 9.29+/-1.08 vs. 10.57+/-1.16, both P < 
      0.05]; in addition, the cTnT, IVST, LVMI were significantly lowered after the 
      treatment in HFHD group compared with those before treatment [cTnT (mug/L): 
      0.014+/-0.005 vs. 0.028+/-0.011, IVST (mm): 7.81+/-1.69 vs. 11.04+/-2.23, LVMI (g/m(2)): 
      149.10+/-15.77 vs. 158.70+/-17.25, all P < 0.05], and the LVEF were significantly 
      increased in HFHD group as compared with those before treatment (0.574+/-0.068 vs. 
      0.528+/-0.082, P < 0.05). CONCLUSIONS: HFHD has obvious advantages than the routine 
      HD in improving cardiac function of uremia patients.
FAU - Tang, Ling
AU  - Tang L
AD  - Department of Nephrology, the Second People's Hospital of Guiyang, Guiyang 
      550081, Guizhou, China (Tang L, Deng XF, Dai Q, Xiao HF, Shu Y); Department of 
      B-Ultrasound Room, the Second People's Hospital of Guiyang, Guiyang 550081, 
      Guizhou, China (Jiang M); Department of Cardiology, the Second People's Hospital 
      of Guiyang, Guiyang 550081, Guizhou, China (Wei L); Department of Clinical 
      Laboratory, the Second People's Hospital of Guiyang, Guiyang 550081, Guizhou, 
      China (Wang L). Corresponding author: Tang Ling, Email: 84143754@qq.com.
FAU - Deng, Xiaofeng
AU  - Deng X
FAU - Dai, Qing
AU  - Dai Q
FAU - Xiao, Hengfen
AU  - Xiao H
FAU - Shu, Yue
AU  - Shu Y
FAU - Jiang, Min
AU  - Jiang M
FAU - Wei, Ling
AU  - Wei L
FAU - Wang, Li
AU  - Wang L
LA  - chi
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
JT  - Zhonghua wei zhong bing ji jiu yi xue
JID - 101604552
RN  - 0 (Biomarkers)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Biomarkers
MH  - China
MH  - Humans
MH  - Myocardium
MH  - Natriuretic Peptide, Brain
MH  - Prospective Studies
MH  - Renal Dialysis
MH  - *Uremia
EDAT- 2017/06/20 06:00
MHDA- 2018/10/20 06:00
CRDT- 2017/06/20 06:00
PHST- 2017/06/20 06:00 [entrez]
PHST- 2017/06/20 06:00 [pubmed]
PHST- 2018/10/20 06:00 [medline]
AID - 10.3760/cma.j.issn.2095-4352.2017.06.014 [doi]
PST - ppublish
SO  - Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017 Jun;29(6):547-550. doi: 
      10.3760/cma.j.issn.2095-4352.2017.06.014.